BioGaia has signed an agreement with the Swiss bio-pharmaceutical company Ferring Pharmaceuticals. The agreement gives Ferring exclusive rights to sell BioGaia´s Probiotic Drops in Mexico, Brazil and Greece.
BioGaia´s patented Reuteri products provide a simple, safe and effective way of improving gut health. In a series of clinical trials, the company has shown Reuteri´s strong positive effects on colic (see the January 2007 issue of Pediatrics) and its ability to prevent infections caused by bacteria and yeasts. The products will be sold under the BioGaia brand. The registration process will start immediately and launch will take place as soon as approval is obtained, which is estimated to be during 2008.
Ferring already sells BioGaia Probiotic Drops in Spain ("Reuteri Gotas"), Portugal, Canada and the Czech Republic and have the rights to sell BioGaia Probiotic Drops in a number of countries in the Middle East.
"Our existing collaboration with Ferring´s strong marketing organisation and their well-established relations with doctors, particularly paediatricians, has led to excellent results in those countries where the products are already launched. With this new contract we will make our entry into the promising Latin American market" says Peter Rothschild, President BioGaia AB.
Ferring has more than 2500 employees, offices in more than 40 countries
and markets products in approximately 70 countries.
BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the Nordic Stock Exchange in Stockholm.